Journal of Thrombosis and Thrombolysis

, Volume 34, Issue 2, pp 229–234 | Cite as

Diagnostic evaluation of the MRP-8/14 for the emergency assessment of chest pain

  • Amit N. Vora
  • Marc P. BonacaEmail author
  • Christian T. Ruff
  • Petr Jarolim
  • Sabina Murphy
  • Kevin Croce
  • Marc S. Sabatine
  • Daniel I. Simon
  • David A. Morrow


Elevated levels of myeloid-related protein (MRP)-8/14 (S100A8/A9) are associated with first cardiovascular events in healthy individuals and worse prognosis in patients with acute coronary syndrome (ACS). The diagnostic utility of MRP-8/14 in patients presenting to the emergency room with symptoms concerning for ACS is uncertain. MRP-8/14 was measured in serial serum and plasma samples in a single center prospective cohort-study of patients presenting to the emergency room with non-traumatic chest pain concerning for ACS. Final diagnosis was adjudicated by an endpoint committee. Of patients with baseline MRP-8/14 results (n = 411), the median concentration in serum was 1.57 μg/ml (25th, 75th: 0.87, 2.68) and in plasma was 0.41 μg/ml (<0.4, 1.15) with only moderate correlation between serum and plasma (ρ = 0.40). A final diagnosis of MI was made in 106 (26%). Peak serum MRP-8/14 was higher in patients presenting with MI (p < 0.001). However, the overall diagnostic performance of MRP-8/14 was poor: sensitivity 28% (95% CI 20–38), specificity 82% (78–86), positive predictive value 36% (26–47), and negative predictive value 77% (72–81). The area under the ROC curve for diagnosis of MI with MRP-8/14 was 0.55 (95% CI 0.51–0.60) compared with 0.95 for cTnI. The diagnostic performance was not improved in early-presenters, patients with negative initial cTnI, or using later MRP-8/14 samples. Patients presenting with MI had elevated levels of serum MRP-8/14 compared to patients with non-cardiac chest pain. However, overall diagnostic performance of MRP-8/14 was poor and neither plasma nor serum MRP-8/14 offered diagnostic utility comparable to cardiac troponin.


Biomarkers Unstable angina Myocardial infarction Platelets 



Reagent support was provided by Buhlmann Laboratories AG, Switzerland.

Conflicts of interest

The TIMI Study Group has received significant research grant support from Accumetrics, Astra-Zeneca, Bayer Healthcare, Beckman Coulter, Biosite, Bristol-Myers Squibb, CV Therapeutics, Daiichi Sankyo, Eli Lilly and Co, GlaxoSmithKline, Merck and Company, Nanosphere, Novartis Pharmaceuticals, Ortho-Clinical Diagnostics, Pfizer, Roche Diagnostics, Sanofi-Aventis, Schering-Plough, Siemens, and Singulex. Dr. Jarolim has consulted for T2 Biosystems and Quanterix and has received grant support from Daiichi Sankyo, Roche Diagnostics, Amgen, BRAMS, Abbott, and Merck and Co. Dr. Croce was supported in part by NHLBI grant K08HL086672. Dr. Sabatine was supported in part by grant R01 HL096738, grant R01 HL098280, and contract HHSN268201000033C from the NHLBI. Dr. Sabatine also receives research grant support from Abbott, BRAHMS, Critical Diagnostics, Nanosphere, and Roche Diagnostics. Dr. Simon was supported in part by National Institutes of Health grant to DIS (HL57506 MERIT Award). Dr. Morrow has received honoraria for educational presentations from CV Therapeutics, and Sanofi-Aventis. He has served as a consultant for Beckman Coulter, Sanofi-Aventis, Schering Plough, and Siemens. Ms. Murphy and Drs. Bonaca, and Ruff have no additional relationships to report.


  1. 1.
    Wright RS et al (2011) ACCF/AHA focused update incorporated into the ACC/AHA 2007 guidelines for the management of patients with unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 57(19):e215–367PubMedCrossRefGoogle Scholar
  2. 2.
    Kushner FG et al (2009) Focused updates: ACC/AHA guidelines for the management of patients with ST-Elevation Myocardial Infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 54(23):2205–2241PubMedCrossRefGoogle Scholar
  3. 3.
    Thygesen K et al (2007) Universal definition of myocardial infarction. Circulation 116(22):2634–2653PubMedCrossRefGoogle Scholar
  4. 4.
    DeWood MA et al (1980) Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303(16):897–902PubMedCrossRefGoogle Scholar
  5. 5.
    Davies MJ, Thomas AC (1985) Plaque fissuring–the cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina. Br Heart J 53(4):363–373PubMedCrossRefGoogle Scholar
  6. 6.
    Kieffer N et al (1987) Biosynthesis of major platelet proteins in human blood platelets. Eur J Biochem 164(1):189–195PubMedCrossRefGoogle Scholar
  7. 7.
    Newman PJ et al (1988) Enzymatic amplification of platelet-specific messenger RNA using the polymerase chain reaction. J Clin Invest 82(2):739–743PubMedCrossRefGoogle Scholar
  8. 8.
    Morrow DA et al (2008) Myeloid-related protein 8/14 and the risk of cardiovascular death or myocardial infarction after an acute coronary syndrome in the Pravastatin or Atorvastatin Evaluation and Infection Therapy: thrombolysis in myocardial infarction (PROVE IT-TIMI 22) trial. Am Heart J 155(1):49–55PubMedCrossRefGoogle Scholar
  9. 9.
    Vogl T et al (2007) Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 13(9):1042–1049PubMedCrossRefGoogle Scholar
  10. 10.
    Boyd JH et al (2008) S100A8 and S100A9 mediate endotoxin-induced cardiomyocyte dysfunction via the receptor for advanced glycation end products. Circ Res 102(10):1239–1246PubMedCrossRefGoogle Scholar
  11. 11.
    Croce K et al (2009) Myeloid-related protein-8/14 is critical for the biological response to vascular injury. Circulation 120(5):427–436PubMedCrossRefGoogle Scholar
  12. 12.
    Healy AM et al (2006) Platelet expression profiling and clinical validation of myeloid-related protein-14 as a novel determinant of cardiovascular events. Circulation 113(19):2278–2284PubMedCrossRefGoogle Scholar
  13. 13.
    Buhlmann Laboratories AG MRP 8/14 ELISA Package Insert (2009)Google Scholar
  14. 14.
    Morrow DA et al (2007) National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem 53(4):552–574PubMedCrossRefGoogle Scholar
  15. 15.
    Lund J et al (2003) Circulating pregnancy-associated plasma protein a predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 108(16):1924–1926PubMedCrossRefGoogle Scholar
  16. 16.
    Iversen KK et al (2008) Pregnancy associated plasma protein A, a novel, quick, and sensitive marker in ST-elevation myocardial infarction. Am J Cardiol 101(10):1389–1394PubMedCrossRefGoogle Scholar
  17. 17.
    Bayes-Genis A et al (2001) Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med 345(14):1022–1029PubMedCrossRefGoogle Scholar
  18. 18.
    McCann CJ et al (2008) Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T. Eur Heart J 29(23):2843–2850PubMedCrossRefGoogle Scholar
  19. 19.
    Altwegg LA et al (2007) Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes. Eur Heart J 28(8):941–948PubMedCrossRefGoogle Scholar
  20. 20.
    Libby P, Simon DI (2001) Inflammation and thrombosis: the clot thickens. Circulation 103(13):1718–1720PubMedCrossRefGoogle Scholar
  21. 21.
    Furman MI et al (2001) Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. J Am Coll Cardiol 38(4):1002–1006PubMedCrossRefGoogle Scholar
  22. 22.
    Morrow DA (2009) Clinical application of sensitive troponin assays. N Engl J Med 361(9):913–915PubMedCrossRefGoogle Scholar
  23. 23.
    Ionita MG et al (2010) High myeloid-related protein: 8/14 levels are related to an increased risk of cardiovascular events after carotid endarterectomy. Stroke 41(9):2010–2015PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Amit N. Vora
    • 1
  • Marc P. Bonaca
    • 1
    Email author
  • Christian T. Ruff
    • 1
  • Petr Jarolim
    • 3
  • Sabina Murphy
    • 1
  • Kevin Croce
    • 2
  • Marc S. Sabatine
    • 1
  • Daniel I. Simon
    • 4
  • David A. Morrow
    • 1
  1. 1.TIMI Study Group, Department of Medicine, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  2. 2.Cardiovascular Division, Department of Medicine, Brigham and Women’s HospitalHarvard Medical SchoolBostonUSA
  3. 3.Department of PathologyBrigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  4. 4.Harrington-McLaughlin Heart and Vascular Institute, University Hospitals Case Medical Center, Case Western Reserve University School of MedicineClevelandUSA

Personalised recommendations